Remarkably, they showed that the survivors rejected tumor cell rechallenge, along with an anti-tumor memory T cell response, and demonstrated that tumor-infiltrating CD8+ T cells are a key contributor to the superior anti-tumor efficacy of IRE + anti-PD1. Here, CD8A is linked to neoplasm.